New pharmaceutical strategy called for
…impedes R+D endangers long-term survival, and this includes investment constraint caused by serialisation (a new security element in the EU due to take effect on 9 February 2019). The MAGYOSZ member producers spent HUF 65bn (€207m) on R+D in 2016, 17% of national R+D spending.
Sign up now to open the entire news item.You are allowed to open only one news item from PMR websites.
(to send requested information)
(required for new e-mails only)